Exciting Recent Development
After announcing positive top-line results from a large, global Phase III clinical trial that Numoda managed and partially funded through an investment, stakeholders experienced a 46% gain in share price. Since the study began, $83MM in market value was created for our client, as well as a significant licensing deal.
If you would like to learn more about how these results can benefit you please visit us at the JP Morgan 2011 Healthcare Conference. Contact Christopher Mather, SVP Business Affairs, for appointments.
News
Portfolio Company News
Cancer Vaccine Developer Advaxis Taps Numoda For Funds, Clinical Tech
January 2012
Pinnacle Biologics, Inc. Announces The Successful Completion Of A Financing Round
January 2012
With Drugs In Doubt, Some Biotechs Are Selling Out
March 2011
Numoda Capital Buys VitreoRetinal Assets, Seeks To Revive Vision Drug
June 2011
Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug
January 2010
MediQuest Therapeutics Takes Streamlined Route To VC Liquidity
Dow Jones Venture Wire - August 2009
Numoda Capital News
JPMorgan Conference Lifts Biotech VC Hopes For Pharma Deals
Venture Capital Dispatch - WSJ - January 2010
Clinical Trials Manager Heads Into VC
The Wall Street Journal - April 2009
Numoda Seeks $150M Debut Health Fund
Dow Jones Venture Wire - April 2009